Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

, l6 [! I. }- s: a
  m5 e! D3 [1 o0 ~$ Z! N4 Q

' L9 k3 p- ?* r! R3 H+ C9 i& V( t  S3 _9 C2 B! G  M' `
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
/ l' w1 A% A8 |, x
  X" U# w5 }0 F
) r# l: C$ c- H: T6 p
; T' [, @: E8 ]% j. S7 gPluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

bubble_w

求原文

cortex

原文